Related Experiment Video
Updated: Mar 12, 2026
Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis
Published on: May 23, 2021
First case of Roussoella percutanea bursitis
M Almagro-Molto1, A Haas1, C Melcher2
1Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Ludwig-Maximilians-Universitäts-Klinikum, München, Germany.
Abstract:
Roussoella percutanea is a novel opportunistic pathogen firstly identified in 2014. It is known to cause subcutaneous infection in immunosuppressed patients. We report on the first case of R. percutanea bursitis in a renal transplant patient. We provide new data about its identification, drug susceptibility, and treatment outcome. Here we demonstrate that R. percutanea is a potential human pathogen.
Insights
Roussoella percutanea, a fungus identified in 2014, can cause subcutaneous infections. This study details the first reported case of R. percutanea bursitis in a renal transplant recipient.
Area of Science:
- Mycology
- Infectious Diseases
- Transplant Medicine
Background:
- Roussoella percutanea is a recently identified fungus (2014) known to cause opportunistic subcutaneous infections.
- Immunocompromised individuals, particularly those with weakened immune systems, are susceptible to such infections.
Observation:
- This report details the first documented case of R. percutanea causing bursitis in a patient who received a renal transplant.
- The patient's condition involved subcutaneous infection, specifically affecting the bursa.
Findings:
- The study provides novel data on the identification of R. percutanea in a clinical setting.
- Information regarding the drug susceptibility profile of this fungal isolate is presented.
- The treatment outcome for the patient with R. percutanea bursitis is described.
Implications:
- This case highlights R. percutanea as a potential human pathogen, expanding the spectrum of known fungal infections.
- The findings underscore the importance of considering rare fungal pathogens in immunosuppressed patients, especially transplant recipients.
- Further research into R. percutanea is warranted to understand its clinical significance and develop targeted treatment strategies.
